PPIDT00407
Drug Information
| Name | Rozanolixizumab |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB14919 |
| Type | biotech |
| Indication | Rozanolixizumab-noli is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.[L47117, L50973] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, solution | Subcutaneous |
140 mg/ml
|
| Injection, solution | Subcutaneous |
140 mg/1mL
|